<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36176198</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Comparison between PFN1 and SOD1 mutations in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>552</StartPage><EndPage>554</EndPage><MedlinePgn>552-554</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15583</ELocationID><Abstract><AbstractText Label="BACKGROUND">The objective of this study was to characterize the prototypical phenotype of patients with amyotrophic lateral sclerosis (ALS) associated with PFN1 mutations in profilin 1 (PFN1) and to determine clinical indications to test for mutations in this gene.</AbstractText><AbstractText Label="MATERIAL AND METHODS">The phenotype of three relatives carrying the M114V PFN1 mutation are detailed here and are compared with those of patients with ALS linked to PFN1 previously reported in the literature.</AbstractText><AbstractText Label="RESULTS">In this pedigree and in the literature, the main clinical findings which best describe familial ALS linked to PFN1 might be the following characteristics: pedigrees over five cases, age of onset around 50&#x2009;years, site of onset systematically lower limbs and the absence of cognitive impairment.</AbstractText><AbstractText Label="CONCLUSION">First, the infrequent incidence of patients with ALS linked to PFN1 mutation supports the pursuit of a precise characterization of the phenotype linked to PFN1 mutations. Then, the numerous similarities between the phenotype amongst patients linked to SOD1 and PFN1 mutations and between histological features amongst both mice models prompts a review of the current ALS classifications, taking into consideration both phenotype and genotype.</AbstractText><CopyrightInformation>&#xa9; 2022 European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1625-8845</Identifier><AffiliationInfo><Affiliation>CRMR SLA, CHU Bretonneau, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253 iBrain, Inserm, Universit&#xe9; de Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lejeune</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Service de Neurologie, La Roche/Yon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253 iBrain, Inserm, Universit&#xe9; de Tours, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Biochimie et Biologie mol&#xe9;culaire, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltran</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4718-0902</Identifier><AffiliationInfo><Affiliation>CRMR SLA, CHU Bretonneau, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piegay</LastName><ForeName>Anne-Sophie</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>CRMR SLA, CHU Bretonneau, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>Helene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UMR 1253 iBrain, Inserm, Universit&#xe9; de Tours, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Biochimie et Biologie mol&#xe9;culaire, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meininger</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>H&#xf4;pital Priv&#xe9; des Peupliers, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495738">PFN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051304">Profilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051304" MajorTopicYN="N">Profilins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis-genetics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>30</Day><Hour>1</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36176198</ArticleId><ArticleId IdType="doi">10.1111/ene.15583</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084-2098.</Citation></Reference><Reference><Citation>Corcia P, Camu W, Brulard C, et al. Effect of familial clustering in the genetic screening of 235 French ALS families. J Neurol Neurosurg Psychiatry. 2021;92:510-518.</Citation></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17-23.</Citation></Reference><Reference><Citation>Wu CH, Fallini C, Ticozzi N, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488:499-503.</Citation></Reference><Reference><Citation>Alkam D, Feldman E, Singh A, Kiaei M. Profilin1 biology and its mutation, acting in disease. Cell Mol Life Sci. 2017;74:967-981.</Citation></Reference><Reference><Citation>Nekouei M, Aliahmadi A, Kiaei M, Ghassempour AR. Mutant profilin1 aggregation in amyotrophic lateral sclerosis: an in vivo biochemical analysis. Basic Clin Neurosci. 2021;12:213-222.</Citation></Reference><Reference><Citation>Fratta P, Charnock J, Collins T, et al. Profilin1 E117G is a moderate risk factor for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:506-608.</Citation></Reference><Reference><Citation>Smith BN, Vance C, Scotter EL, et al. Novel mutations support a role for profilin 1 in the pathogenesis of ALS. Neurobiol Aging. 2015;36(3):1602.e17-27.</Citation></Reference><Reference><Citation>Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech. 2017;10:537-549.</Citation></Reference><Reference><Citation>Lutz C. Mouse models of ALS: past, present and future. Brain Res. 2018;1693:1-10.</Citation></Reference><Reference><Citation>Yang C, Danielson EW, Qiaoa T, et al. Mutant PFN1 causes ALS phenotypes and progressive motor neuron degeneration in mice by a gain of toxicity. Proc Natl Acad Sci USA. 2016;113(41):E6209-E6218.</Citation></Reference><Reference><Citation>Philips T, Rothstein JD. Rodent models of amyotrophic lateral sclerosis. Curr Protoc Pharmacol. 2015;69:5.67.1-5.67.21.</Citation></Reference><Reference><Citation>Pereira GR, Tellini GH, De Mesquita JF. In silico analysis of PFN1 related to amyotrophic lateral sclerosis. PLoS One. 2019;14(6):e0215723. doi:10.1371/journal.pone.0215723</Citation></Reference><Reference><Citation>Yamashita S, Ando Y. Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. Transl Neurodegener. 2015;4:13. doi:10.1186/s40035-015-0036-y eCollection 2015.</Citation></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109-119. doi:10.1056/NEJMoa2003715</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>